TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Wound Infiltration With Bupivacaine/Adrenalin During Cesarean Section and Postoperative Pain.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* cesarean section with regional anesthesia~* singleton~* pfannenstiel incision~Exclusion Criteria:~* cesarean section with general anesthesia~* maternal liver or kidney disease~* allergy to Bupivacaine~* allergy to Adrenalin~* intrauterine fetal death~* major fetal malformations

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: EXPERIMENTAL): Infiltration of the subcutaneous layer with local anesthetic and combined with adrenaline.
- control (Type: NO_INTERVENTION): Abdominal layers will be closed without Infiltration .

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Anticoagulants Comparative Benefit-risk Ratio in Real Life

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~Patients with NVAF with a first reimbursed dispensation of Pradaxa®, Xarelto®, or VKA in 2013, with no other identified indication for anticoagulation; Without any VKA or NOAC (Pradaxa®, Xarelto®, or Eliquis®) reimbursed dispensation for the last 3 years before the first reimbursed dispensation of Pradaxa®, Xarelto®, or VKA~Exclusion criteria:~None

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NOAC (Type: None): New oral anticoagulant groups
- VKA (Type: None): VKA group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Radiation Therapy With or Without Chemotherapy in Treating Patients With Head and Neck Cancer That Has Been Removed During Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS: Biopsy-proven squamous cell carcinoma of one of the following sites: Hypopharynx Larynx Oral cavity Oropharynx At least 1 of the following high-risk factors required: Histologic extracapsular nodal extension Histologic involvement of 2 or more regional lymph nodes Microscopically positive mucosal margins Complete resection of all visible and palpable disease Therapy must begin within 8 weeks of tumor-related surgery Bilateral resections may or may not be performed simultaneously Eligibility window begins with first definitive surgery Neck dissection not required for T4 N0, truly midline supraglottic tumors No tumors of the lip, nasopharynx, or sinuses No synchronous or concurrent head and neck tumors No evidence of distant metastasis Concurrent registration on Fixed Tumor Repository Study allowed~PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 60%-100% Hematopoietic: WBC at least 3,500 Platelets at least 100,000 Hepatic: Not specified Renal: Creatinine clearance greater than 50 mL/min Other: No medical contraindication to protocol therapy No second malignancy within 5 years No pregnant or nursing women~PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior chemotherapy Endocrine therapy: Not specified Radiotherapy: No prior radiotherapy to head and neck region Surgery: See Disease Characteristics

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Radiation therapy (Type: ACTIVE_COMPARATOR): Radiation therapy - 60 Gy in 6 weeks (2 Gy once a day, 5 x a week)
- Radiation therapy plus cisplatin (Type: EXPERIMENTAL): Radiation therapy - 60 Gy in 6 weeks (2 Gy once a day, 5 x a week) plus Cisplatin-100 mg/m2 i.v. on days 1,22 and 43 with radiation therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Influence of Glutamate on Memory in Humans

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* German native language or native language level~* Able to give written informed consent~* right-handed~Exclusion Criteria:~* inability to give written informed consent, underaged minors, contractually incapable persons, persons in legal custody~* any psychiatric, neurological or internal illness~* hematoporphyria (enzyme sickness)~* intake of medication (except oral contraceptives)~* simultaneous participation in other clinical studies~* hypersensitivity to Memantine or other anti-dementia substances, or to D-Cycloserine~* alcohol abuse~* epilepsy~* depression~* serious anxiety or psychosis~* serious kidney insufficiency~* intake of Ethionamide or Isoniazide~* pregnancy or women who are nursing~* liver or kidney problems~* intake of NMDA-antagonists, such as Amantadine, Ketamine, or Dextromethorphan~* vegetarians~* stomach ulcer, if treated with medication~* renal tubular acidosis~* urinary infections (with proteus bacteria)~* recent heart attack, heart failure, or uncontrolled high blood pressure~* intake of L-Dopa, dopaminergic agonists, and anticholinergics~* intake of barbiturates, spasmolytics, Phenytoin, Amantadine, oral coagulators, warfarin, HCT (Hydrochlorothiazide)~* heart or cranial operations~* pacemaker, medication pump (such as insulin pump), hearing aid, removable prosthodontics~* metal in or on body (such as acupuncture needles, artificial limbs, stents, metal splints, clips, implanted electrodes, tattoos, or piercings)~* claustrophobia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- Sugar pill, behavioral glutamic acid (Type: PLACEBO_COMPARATOR): Placebo condition for D-Cycloserine
- Sugar pill, fMRI, glutamic acid (Type: PLACEBO_COMPARATOR): Placebo condition for D-Cycloserine, fMRI
- Sugar pill, memantine, behavioral (Type: PLACEBO_COMPARATOR): Placebo condition Memantine, behavioral
- Sugar pill, memantine, fMRI (Type: PLACEBO_COMPARATOR): Placebo condition Memantine, fMRI
- D-Cycloserine behavioral (Type: ACTIVE_COMPARATOR): None
- D-Cycloserine, fMRI (Type: ACTIVE_COMPARATOR): None
- Memantine, behavioral (Type: ACTIVE_COMPARATOR): None
- Memantine, fMRI (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety of Two Trivalent Influenza Vaccines Evaluated in Children and Adolescents 4 to 17 Years of Age

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~- Healthy subjects 4-17 years of age~Exclusion Criteria:~* Subjects who are not healthy,~* Subjects who are pregnant or breast feeding,~* Subjects with a history of severe allergic reaction or allergic to any of the vaccine components.

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 17 Years
- Healthy Volunteers: t

Study Arms:
- TIVc (Type: EXPERIMENTAL): Subjects ≥4 to ≤17 years of age received one or two doses of mammalian cell-culture-derived trivalent influenza vaccine based on their previous vaccination status.
- TIVf (Type: ACTIVE_COMPARATOR): Subjects ≥4 to ≤17 years of age received one or two doses of egg-derived trivalent influenza vaccine based on their previous vaccination status.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The PK/PD Study of SHR2285 Tablets in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. males or females, aged 18-45~2. subjects with no cardiovascular disease, sitting blood pressure: 90mmHg ≤SBP\<140mmHg and 50mmHg ≤DBP\<90mmHg;~3. body mass index (BMI) between 18 to 28, and a total body weight: male ≥50.0 kg and \<90.0 kg; female ≥45.0 kg and \<90.0 kg~4. Participant in general good health. No clinically significant findings in laboratory parameters or clinically significant abnormality on X-ray~Exclusion Criteria:~1. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) or total bilirubin \> 1X ULN during screening/baseline;~2. Abnormal coagulation function;~3. A clinical history of coagulation dysfunction；subjects with adverse reaction of antiplatelet drugs or anticoagulant drugs.~4. Subjects with severe trauma or surgery within 3 months prior to the screening；~5. Known blood donation within 30 days pre-dose; donating≥400 ml of blood 3 months pre-dose;~6. Human immunodeficiency virus antibody (HIV-ab), syphilis serological examination, hepatitis b virus surface antigen (HBsAg), hepatitis c virus antibody (HCV-ab) were positive;~7. 3 months prior to screening involved in any drug or medical device clinical subjects, or within 5 half-life of drugs before screening;~8. Pregnant or Serum β-hCG \> 5mIU/mL at baseline or women who are breastfeeding; etc.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- SHR2285 (Type: EXPERIMENTAL): Up to 7 cohorts of healthy subjects will receive a single dose of oral SHR2285 tablet.
- Placebo (Type: EXPERIMENTAL): Up to 7 cohorts of healthy subjects will receive a single dose of oral placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Nevirapine Plus Zidovudine to Prevent Perinatal HIV in Thailand

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Pre-Entry Criteria~Women were eligible for the study if they:~* have evidence of HIV infection (documented by two HIV antibody tests on two different dates);~* were to be provided ZDV Prophylaxis (starting at 28 weeks or as soon as possible thereafter);~* intended to carry the pregnancy to term;~* intended to deliver at and bring their infant to a study site for at least 12 months after delivery; and~* could provide informed consent.~Inclusion criteria~Women are eligible for the study if they:~* met all pre-entry criteria;~* agreed not to breastfeed;~* consented to participate and to be followed for the duration of the study;~* presented the following laboratory values within 14 days prior to randomization:~* hemoglobin \> 8.0 mg/dl~* absolute neutrophil count \> 1000 cells/mm3~* platelets \> 100,000 cells/mm3~* serum creatinine \< 1.5 mg/dl (women with a serum creatinine \> 1.5 mg/dl must have a measured eight-hour urine creatinine clearance \> 70 ml/min)~* SGPT less than 10 times the upper limit of normal NOTE: Women with a Grade 2 or Grade 3 SGPT value (between 2.6 and 10 times the upper limit of normal) were allowed on study; they were monitored monthly until delivery. If at any point their SGPT value rose to a Grade 4 (more than 10 times the upper limit of normal), they should not be dosed with the Study Drug.~Exclusion Criteria:~* evidence of pre-existing fetal anomalies incompatible with life;~* known hypersensitivity to any benzodiazepine or to NVP;~* receipt of antiretroviral agent other than ZDV;~* receipt of non-allowed concomitant treatment;~* uncontrolled hypertension;~* concurrent participation in another clinical trial;~* women with a CD4 count \<200/µL or history of oral candidiasis if they were not receiving PCP prophylaxis.

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): One dose maternal NVP treatment at onset of labor, and one dose of infant NVP treatment 48-72 hours after birth (NVP-NVP)
- 2 (Type: EXPERIMENTAL): One dose maternal NVP treatment at onset of labor, and one dose of infant placebo 48-72 hours after birth. (NVP-Placebo)
- 3 (Type: PLACEBO_COMPARATOR): One dose maternal placebo at onset of labor, and one dose of infant placebo 48-72 hours after birth. This was the reference study arm. (Placebo-Placebo)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of 3 Versus 10 Days of Antibiotics in Skin Abscesses After Surgical Drainage

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients presenting with a skin abscess that requires surgical drainage (induration ≥ 1 cm in diameter)~* minimally invasive surgical technique with the insertion of a subcutaneous drain can be utilized on the patient~Exclusion Criteria:~* patients requiring immediate hospitalization~* patients who have received 2 or more doses of antibiotics in the previous 36 hours~* patients with diabetes, sickle-cell disease, an immuno-compromising disease, an underlying medical condition predisposing the patient to frequent hospitalizations or medical visits, or indwelling catheters or percutaneous medical devices~* patients with a concurrent, non-abscess infection~* patients with an allergy to Trimethoprim-sulfamethoxazole

- Gender: ALL
- Minimum Age: 3 Months
- Maximum Age: 17 Years
- Healthy Volunteers: t

Study Arms:
- 10 days of Trimethoprim-Sulfamethoxazole (Type: ACTIVE_COMPARATOR): Oral Trimethoprim-Sulfamethoxazole dosed at 10 mg Trimethoprim/kg/day divided twice a day, to a maximum of 640 mg Trimethoprim/day
- 3 days of Trimethoprim-Sulfamethoxazole (Type: EXPERIMENTAL): Oral Trimethoprim-Sulfamethoxazole dosed at 10 mg Trimethoprim/kg/day divided twice a day, to a maximum of 640 mg Trimethoprim/day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Multi-Centre Trial Comparing Three Artemisinin-Based Combination Treatments on P. Falciparum Malaria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* age at least 6 months,~* weight at least 5 kg,~* residing in one of the four countries (Mali, Cameroon, Sudan, Rwanda),~* able to receive oral treatment,~* having an axillary body temperature of more than 37,5 degrees Celsius or history of fever within the proceeding 24 hours,~* suffering from a mono specific P. falciparum infection with a parasite density between 2000 and 200000 asexual forms per micro litre of blood.~Exclusion Criteria:~* presence of severe or complicated malaria (WHO 2000),~* severe concomitant pathology or one that needs a medical follow-up incompatible with the study,~* allergic to one of the drugs involved in this study,~* pregnant (reported pregnancy, detected clinically or with the β HCG test),~* use of one of the anti-malaria drugs involved in this study during 28 days preceding inclusion.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Brain Imaging of Cannabinoid Receptors

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
* Female, healthy adult volunteers who are either MJ users and nonusers (controls)~* 18-45 years of age~* serum creatinine and hepatic enzymes (AST, ALT) must be within the normal limits~* Women of child bearing potential must meet one of the following three criteria:~  1. negative pregnancy test by serum pregnancy test 2 .Following a reliable method of birth control 3. Agreeing to follow a reliable method of birth control during the study and for 1 month following all study procedures~Additional inclusion criteria for MJ users~* Regular MJ use~* present MJ positive urine~* meet Diagnostic and Statistical Manual, version 5 (DSM-5) criteria for cannabis use disorder (CUD)~Additional inclusion non-users~* report no MJ use~* present a MJ-negative urine~Exclusion Criteria:~* \< 5th grade reading level~* Current Diagnostic and Statistical Manual, version 5 (DSM-5) psychiatric disorder;~* Current DSM-5 alcohol or substance use disorder (excluding MJ or nicotine)~* Recent Illicit drug use or positive drug test~* Using MJ under the guidance of MD;~* History of seizures, closed head trauma;~* unstable hypertension;~* conditions preventing magnetic resonance imaging (MRI) such as implanted metal, claustrophobia, or anatomical abnormalities (e.g., enlarged ventricles, brain lesions);~* Use of medications or herbal supplements which may be counter indicated as determined by study physician~* Have had exposure to ionizing radiation that in combination with the study's estimated radiation exposure would result in a cumulative exposure that exceeds recommended exposure limits of 5 rem per year.~* Presence or history of drug allergy, or allergic disease diagnosed and treated by a physician.~* any serious medical condition in whom participation is contraindicated.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Cannabis users (Type: ACTIVE_COMPARATOR): Smoked Cannabis plant material (0 and 25 mg THC) will be administered to volunteers who are regular cannabis users. Cannabis users will also complete a PET scan where 20 millicurie of 11C-OMAR
- Nonuser controls (Type: ACTIVE_COMPARATOR): No cannabis administration. Non-user controls will complete a PET scan where 20 millicuries of 11C-OMAR

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Contingent Incentives Plus Bupropion for Smoking in People With Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~Diagnosis of schizophrenia or schizoaffective disorder, smoke 20-50 cpd, clinically stable on antipsychotic and antidepressant medications~Exclusion Criteria:~Pregnant/nursing women, seizure disorder, lowered seizure threshold due to other medical conditions, positive urine drug screen positive breath alcohol test, past 2 weeks use of MAO inhibitors, any form of bupropion, cimetidine, phenobarbital, phenytoin, DA agonists, anorectics, stimulants

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): Contingent reinforcement plus bupropion
- 2 (Type: EXPERIMENTAL): Contingent reinforcement plus placebo
- 3 (Type: EXPERIMENTAL): Non-contingent reinforcement plus bupropion
- 4 (Type: PLACEBO_COMPARATOR): Non-contingent reinforcement plus placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intermittent Preventive Treatment With Azithromycin-containing Regimens in Pregnant Women in Papua New Guinea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* pregnant~* 14-26 weeks'gestation~* permanent resident of study area~* exclusive use of study health facilities for primary health care~* Age is between 16 and 49 years~Exclusion Criteria:~* Known chronic illness, e.g. TB, diabetes, renal failure~* Severe anaemia requiring hospitalisation (Hb \< 6 g/dl accompanied by symptoms requiring urgent treatment)~* permanent disability, that prevents or impedes study participation and/or comprehension~* Known multiple pregnancy

- Gender: FEMALE
- Minimum Age: 16 Years
- Maximum Age: 49 Years
- Healthy Volunteers: t

Study Arms:
- SP, chloroquine treatment; bed net (Type: ACTIVE_COMPARATOR): Treatment course of sulphadoxine pyrimethamine and chloroquine on enrolment. Long lasting insecticide treated bed net
- 3 x SP plus azithromycin; bed nets (Type: EXPERIMENTAL): Three x monthly courses of azithromycin and sulphadoxine pyrimethamine plus long lasting insecticide treated bed net.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Breast Cancer Progressing After First-Line Therapy With Avastin and Chemotherapy (TANIA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female patients, \>/= 18 years of age~* Histologically confirmed HER2-negative breast cancer~* Disease progression during or following first-line treatment with Avastin and chemotherapy for locally recurrent or metastatic breast cancer~* Avastin treatment in first-line setting must have been a minimum of 4 cycles (15 mg/kg) or 6 cycles (10 mg/kg) in combination with chemotherapy~* ECOG performance status 0-2~* At least 28 days since prior radiation therapy or surgery and recovery from treatment~Exclusion Criteria:~* Anti-angiogenic therapy or anti-vascular endothelial growth factors other than Avastin for first-line treatment~* Active malignancy other than superficial basal cell and superficial squamous cell carcinoma of the skin, or in situ carcinoma of the cervix or breast within the last 5 years~* Inadequate renal function~* Clinically relevant cardio-vascular disease~* Known CNS disease except for treated brain metastases~* Chronic daily treatment with high-dose aspirin (\>325 mg/day) or clopidogrel (\>75 mg/day)~* Pregnant or lactating women

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): None
- 2 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete